Berapakah harga Neumora Therapeutics, Inc. Common Stock (NMRA)

Harga Neumora Therapeutics, Inc. Common Stock (NMRA) adalah $1.37

Apakah topi pasaran Neumora Therapeutics, Inc. Common Stock (NMRA)

Cap pasaran Neumora Therapeutics, Inc. Common Stock (NMRA) adalah $254.58M

Hasil Neumora Therapeutics, Inc. Common Stock (NMRA)

Neumora Therapeutics, Inc. is a specialized biopharmaceutical company progressing through clinical trials, dedicated to advancing therapies for a range of neurological, psychiatric, and neurodegenerative conditions. Its most advanced candidate, navacaprant (also known as NMRA-140), is a novel, once-daily oral kappa opioid receptor antagonist currently undergoing Phase 3 clinical trials for the management of major depressive disorder. Additionally, NMRA-511 is in Phase 1 studies, targeting agitation experienced by individuals with Alzheimer's-related dementia. Another compound, NMRA-266, is also in Phase 1 clinical development, aimed at addressing schizophrenia and other related neuropsychiatric conditions. Beyond its clinical programs, Neumora maintains a preclinical pipeline featuring several promising candidates: NMRA-NMDA for schizophrenia, NMRA-CK1d (a CK1d inhibitor initiative) for amyotrophic lateral sclerosis (ALS), NMRA-NLRP3 for specific neurodegenerative ailments, and NMRA-GCase for Parkinson's disease. Tracing its origins to a 2019 incorporation, the company, initially known as RBNC Therapeutics, Inc., adopted its current name, Neumora Therapeutics, Inc., in October 2021. Its corporate headquarters are situated in Watertown, Massachusetts.

Tahun	Hasil	Ubah
Tidak cukup data untuk tarikh yang disediakan.

Tahun

Hasil

Ubah

Tidak cukup data untuk tarikh yang disediakan.

Syarikat	Hasil	Perbezaan Hasil	Negara
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Moderna, Inc. MRNA.US	$2.23B	-	US
CSL Limited CSL.AX	$15.74B	-	AU
Lonza Group AG LONN.SW	-	-	CH

Syarikat

Hasil

Perbezaan Hasil

Negara